Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has increased from $2.7m to $5.1m.
The expanded scope will see Ixico providing additional imaging services, to a significantly higher number of patients, and an increased number of participating international study sites.
IXICO chief executive Giulio Cerroni said: “I am delighted that our client has decided to expand our involvement in this important study.
“We value the strength of our relationships with biopharmaceutical companies and our ability to provide them with important insights that support their efforts to bring new therapies to market. This latest increase in scope demonstrates IXICO’s ability to efficiently scale operations and adapt to changing requirements as global clinical studies progress.”
Ixico is dedicated to delivering insights in neuroscience. The company aims to transform the progression of our biopharmaceutical clients’ neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.
Ixico’s data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes.
Source: Company Press Release